12 Best German Stocks to Buy According to Hedge Funds

2. Immatics (NASDAQ:IMTX)

Number of Hedge Fund Holders: 33

Immatics (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company that develops T-cell redirecting immunotherapies for cancer with a focus on solid tumors. Its pipeline includes TCR-engineered cell therapies and TCR bispecific that use the body’s immune system to target and destroy cancer cells.

The company’s primary growth driver is its ACTengine® IMA203 TCR-T cell therapy program which targets PRAME. It has a strong focus on its Phase 3 SUPRAME trial in advanced melanoma. The company has initiated this randomized-controlled trial to evaluate IMA203 with the aim of potential market entry by 2027. Positive Phase 1b data shows a 54% confirmed objective response rate and a 12.1-month median duration of response in melanoma patients. The SUPRAME trial is projected to complete patient enrollment in 2026, with a BLA submission planned for Q1 2027.

Immatics (NASDAQ:IMTX) is advancing its second-generation IMA203CD8 TCR-T which demonstrated enhanced potency in Phase 1a trials and expanded application to other solid tumors like ovarian cancer. The company’s TCR Bispecific programs, which include TCER® IMA402 (PRAME) and IMA401 (MAGEA4/8), are progressing through Phase 1 trials and showed promising initial anti-tumor activity. With $628 million in cash reserves as of December 31, 2024, the company is funded to support these clinical advancements, with an updated cash runway extending into H2 2027.